Your session is about to expire
← Back to Search
Part 1 TPST-1120 for Oral Squamous Cell Carcinoma
Study Summary
This trial is testing a new cancer drug (TPST-1120) to see if it is safe and works well against tumors.
- Oral Squamous Cell Carcinoma
- Non-Small Cell Lung Cancer
- Gastroesophageal Cancer
- Prostate Cancer
- Bile Duct Cancer
- Kidney Cancer
- Bladder Cancer
- Pancreatic Cancer
- Liver Cancer
- Squamous Cell Carcinoma
- Breast Cancer
- Colorectal Cancer
- Sarcoma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
For what health concerns is Part 1 TPST-1120 typically prescribed?
"Part 1 TPST-1120 is frequently used to combat malignant neoplasms, as well as other conditions such as metastatic esophageal adenocarcinoma and unresectable melanoma or squamous cell carcinoma."
Does this research initiative represent a pioneering endeavor?
"Since 2012, Part 1 TPST-1120 has been the subject of an ongoing exploration. Ono Pharmaceutical Co. Ltd was responsible for its initial clinical trial in 2012, which concluded with 659 participants and subsequently granted Phase 1 & 2 drug approval. At present, 717 live studies exist across 2356 cities and 49 nations worldwide."
Has the regulatory agency sanctioned TPST-1120 Part 1?
"Despite limited clinical evidence, Part 1 TPST-1120 is believed to be relatively safe and was thus assigned a score of 1."
Are there any other experiments that have utilized Part 1 TPST-1120?
"The first trial of Part 1 TPST-1120 began in 2012 at Local Institution. 250 studies have since been completed, and 717 more are currently active - the majority hosted out of Ann Arbor, Michigan."
How many participants are being treated in this therapeutic research study?
"Unfortunately, this trial is not presently recruiting. It was first posted on March 20th 2019 and updated for the last time November 1st 2022. If you are looking for alternative studies, there are currently 4723 ongoing clinical trials focussed on cholangiocarcinoma and 717 Part 1 TPST-1120 research projects in search of participants."
How many medical establishments are conducting this experiment?
"The University of Michigan Rogel Cancer Center in Ann Arbor, the UPMC Hillman Cancer Centre in Pittsburgh, and the University of California - San Francisco are all participating sites for this medical trial. Additionally, there are 11 other locations hosting this clinical research."
Is enrollment still open for this experimental research?
"This clinical trial is no longer taking on new participants. The study was posted in March of 2019 and last updated November 1st 2022, but if you are looking for other research options there are 4723 trials with cholangiocarcinoma actively recruiting patients as well as 717 Part 1 TPST-1120 studies enrolling volunteers."
Who else is applying?
What state do they live in?
How old are they?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger